32.78 USD
-1.5 (-4.38%)
32.78 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to MLYS. MLYS was compared to 525 industry peers in the Biotechnology industry. MLYS has a great financial health rating, but its profitability evaluates not so good. MLYS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- MLYS had negative earnings in the past year.
- MLYS had a negative operating cash flow in the past year.
- MLYS had negative earnings in each of the past 5 years.
- In the past 5 years MLYS always reported negative operating cash flow.
1.2 Ratios
- MLYS has a better Return On Assets (-28.56%) than 68.57% of its industry peers.
- With a decent Return On Equity value of -29.73%, MLYS is doing good in the industry, outperforming 76.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.56% | ||
| ROE | -29.73% | ||
| ROIC | N/A |
ROA(3y)-46.99%
ROA(5y)-109.19%
ROE(3y)-50.27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MLYS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- The number of shares outstanding for MLYS has been increased compared to 1 year ago.
- MLYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- MLYS has an Altman-Z score of 65.33. This indicates that MLYS is financially healthy and has little risk of bankruptcy at the moment.
- MLYS has a Altman-Z score of 65.33. This is amongst the best in the industry. MLYS outperforms 97.14% of its industry peers.
- MLYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 65.33 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- MLYS has a Current Ratio of 25.50. This indicates that MLYS is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of MLYS (25.50) is better than 97.33% of its industry peers.
- A Quick Ratio of 25.50 indicates that MLYS has no problem at all paying its short term obligations.
- MLYS has a better Quick ratio (25.50) than 97.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 25.5 | ||
| Quick Ratio | 25.5 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 9.79% over the past year.
EPS 1Y (TTM)9.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 22.13% on average over the next years. This is a very strong growth
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.55%
EPS Next 2Y17.28%
EPS Next 3Y7.95%
EPS Next 5Y22.13%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- MLYS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year MLYS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.28%
EPS Next 3Y7.95%
5. Dividend
5.1 Amount
- No dividends for MLYS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MINERALYS THERAPEUTICS INC / MLYS FAQ
Can you provide the ChartMill fundamental rating for MINERALYS THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to MLYS.
What is the valuation status of MINERALYS THERAPEUTICS INC (MLYS) stock?
ChartMill assigns a valuation rating of 0 / 10 to MINERALYS THERAPEUTICS INC (MLYS). This can be considered as Overvalued.
Can you provide the profitability details for MINERALYS THERAPEUTICS INC?
MINERALYS THERAPEUTICS INC (MLYS) has a profitability rating of 1 / 10.
How financially healthy is MINERALYS THERAPEUTICS INC?
The financial health rating of MINERALYS THERAPEUTICS INC (MLYS) is 8 / 10.
What is the earnings growth outlook for MINERALYS THERAPEUTICS INC?
The Earnings per Share (EPS) of MINERALYS THERAPEUTICS INC (MLYS) is expected to grow by 30.55% in the next year.